Potential of the aminosterol, squalamine in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis lung carcinoma

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2567-2573

  Teicher, Beverly A ^a,c   Williams, Jon I ^b   Takeuchi, Hideya ^a   Ara, Gulshan ^a   Herbst, Roy S ^a   Buxton, David ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Genaera Corporation   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Antiangiogenic agents; Combination therapy; Hypoxia; Squalamine; Tumor oxygenation

Indexed keywords

AMINE; AMINOSTEROL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; PACLITAXEL; SQUALAMINE; STEROL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEWIS CARCINOMA; MOUSE; NONHUMAN; OXYGEN ELECTRODE; OXYGENATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL DIVISION; CHOLESTANOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OXYGEN; OXYGEN CONSUMPTION; PACLITAXEL; PARTIAL PRESSURE; RATS; RATS, INBRED F344;

EID: 0031864882     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Folkman J and Ingber D: Inhibitionofangiogenesis. Seminarsin Cancer Biol 3: 89-96, 1992.
2. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 285: 1182-1186, 1971.
3. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416, 1972.
4. Goldfarb RH and Brunson KW: Therapeutic agents for treatment of established metastases and inhibitors of metastatic spread: preclinical and clinical progress. Curr Opinion Oncol 4: 1130-1141, 1992.
5. Teicher BA: Angiogenesis and cancer metastases: therapeutic approaches. Crit Rev Oncology Hematology 20: 9-39, 1995.
6. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl J Med 324: 1-8, 1991.
7. Mattem J, Koomagi R, and Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epiderrnoid lung carcinoma. Brit J Cancer 73: 931 -934, 1996.
8. Lindmark G, Gerdin B, Sundberg C, et al: Prognostic significance ofthe microvascular count in colorectal cancer. J Clin Oncol 14: 461-466, 1996.
9. Weidner N, Folkman J: Tumoral vascularity as a prognostic factor in cancer, In: Important Advances in Oncology 1996 (DeVita, V.T, Hellman, S, and Rosenberg, S.A, eds.), Lippincott-Raven Publishers, Philadelphia, PA, pp. 167-190, 1996.
10. Fontanini G, Lucchi M, Signati S, et al: Angiogenesis as a prognostic indicatior of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89: 881-886, 1997.
11. Folkman J: Antiangiogenic Therapy. Cancer: Principals & Practice of Oncology, 3075-3086, 1997.
12. Gross J, Azizkhan RG, Biswas C, et al: Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci USA 78: 1176-1180, 1981.
13. Folkman J, Langer R, Linhardt et al: Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719-725, 1983.
14. Folkman J, and Ingber DE: Angiostatic steroids. Ann Surg 206: 374-383, 1987.
15. Crum R, Szabo S, and Folkman J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230: 1375-1378, 1985.
16. Ingber DE, Madri JA, and Folkman J: A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 119: 1768-1775, 1986.
17. Mira-y-Lopez R, Reiche E, Stolfi RL, et al: Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma. Cancer Res 45: 2270-2276, 1985.
18. Drago JR, Curley RM, and Sipio JC: Nb rat prostate adenocarcinoma model: metastasis. Anticancer Res 5: 193-196, 1985.
19. Drago JR, and Lombard JS: Metastasis in the androgen-insensitive Nb rat prostatic carcinoma system. J. Surg Oncol 28: 252-256, 1985.
20. Ziehe M, Ruggiero M, Pasquali F, et al: Effects of cortisone with and without heparin on angiogenesis induced by prostaglandin E 1 and by S 180 cells, and on growth of murine transplantable tumours. Int J Cancer 55: 549-552, 1985.
21. Sakamoto N, Tanaka NG, Tohgo A, et al: Heparin plus cortisone acetate inhibit tumor growth by blocking endothelial cell proliferation. Cancer J 1: 55-58, 1986.
22. Sakarnoto N, Tanaka NG, Tohgo A, et al: Inhibitory effects of heparin plus cortisone acetate on endothelial cell growth both in cultures and in tumor masses. J Natl Cancer Inst 78: 581-585, 1987.
23. Penhaligon M, and Camplejohn RS: Combination heparin plus cortisone treatment of two transplanted tumors in C3H/He mice. J Natl Cancer Inst 74: 869-873, 1985.
24. Teale DM, Underwood JCE, Potter CW, et al: Therapy of spontaneously metastatic HSV-2 induced hamster tumours with cortisone acetate administered with or without heparin. Eur J Cancer Clin Oncol 23: 93-100, 1987.
25. Zeidman I: The fate of circulating tumor cells II. A mechanism of cortisone action in increasing metastases. Cancer Res 22: 501-503, 1961.
26. Bhakoo HS, Paolini NS, Milholland RJ, et al: Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma. Cancer Res 41: 1695-1701, 1981.
27. Sakamoto N, and Tanaka NG: Effect of angiostatic steroid with or without glucocorticoid activity on metastasis. Inv Metastasis 7: 208-216, 1987.
28. Tominaga T, Kitamura M, Hayashi K, et al: Effects of high-dose oral administration of medroxyprogesterone acetate (MPA) on the patients with advanced breast cancer. Jap J Cancer Chemother 8: 1727-1730, 1981.
29. Jakobsen A, Frederiksen PL, Moller K, et al: Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22: 1067-1072, 1986.
30. Dowsett M, Lal A, Smith IE, et al: The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. Brit J Cancer 55: 311-313, 1987.
31. Moore KS, Wehrli S, Roder H, et al: Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 90: 1354-1358, 1993.
32. Sills AK, Jr, Epstein D, Sipos EP, et al: Inhibition of tumor-induced neovascularization by squalamine, a novel angiogenesis inhibitor. Poster #1435 at the 64th Annual Meeting of fhe American Association of Neurological Surgeons, Minneapolis, MN, 1996.
33. th Annual Meeting of the American Association of Neurological Surgeons, Minneapolis. MN, 1996.
34. Sills AK, Jr, Tyler B, Laterra J, et al: Squalamine blocks endothelial activation by common brain tumor mitogens. Abstract from First Scientific Meeting, Society for Neuro-Oncology, Santa Fe, NM, 1996.
35. + exchanger isoform, NHE-3. Poster #514 from FASEB Annual Meeting in New Orleans, 1996.
36. + exchanger is phosphorylated in human platelets in response to activating agents. FEBS Letters 284: 219-222, 1991.
37. Teicher BA, Dupuis NP, Liu F, et al: Administration of a hemoglobin - solution decreases hypoxia and increases radiation response in a rat mammary carcinoma. Drug Development Res 34: 231-240, 1995.
38. Teicher BA, Holden SA, Dupuis NP, et al: Oxygenation of the rat 9L gliosarcoma and the rat 13762 mammary carcinoma with various doses of a hemoglobin solution. Art. Cells, Blood Subs, & Immob Biotech 22: 827-833, 1994.
39. Teicher BA, Holden SA, Eder JP, et al: Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 17(1 [suppl 3]), 18-32, 1990.
40. Teicher BA, Ara G, Menon K, et al: In vivo studies with interleukin-12 alone and in combination with monocyte-colony stimulating factor and/or fractionated radiation therapy. Int J Cancer 65: 80-84, 1995.
41. Moore KS, Wehrli S, Roder H, et al: Squalamine: An aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 90: 1354-1358, 1993.
42. Deng G, Dewa T, Regen SL: A Synthetic Ionophore That Recognizes Negatively Charged Phospholipid Membranes. J Am Chem Soc 118: 8975-8976, 1996.
43. Selinsky BS, Zhou Z, Fojtik KG, et al: The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles. Bioch Bioph Acta 1998, in press, 1998.
44. Williams JI, Mangold G, Zasloff M, von Hoff DD: Evaluation of the natural aminosterol squalamine as adjunctive chemotherapy in the MX-1 breast cancer xenograft model. Breast Cancer Res Treat 46: 30, 1997.
45. Parker MG, ed.: Steroid Hormone Action. IRL Press, New York, NY, 1993.
46. Ashino-Fuse H, Takano Y, Oikawa T, et al: Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44: 859-864, 1989.
47. Wolff JEA, Guerin C, Laterra J, et al: Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res 604: 79-85, 1993.
48. Pepper MS, Vassalli J-D, Wilks JW, et al: Modulation of bovine microvcascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J Cell Biochem 55: 419-434, 1994.
49. Yamamoto T, Terada N, Nishizawa Y, et al: Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 56: 393-399, 1994.
50. Blei F, Wilson EL, Mignatti P, et al: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155: 568-578, 1993.
51. Ingber D, and Folkman J: Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59: 44-51, 1988.
52. Oikawa T, Hiragun A, Yoshida Y, et al: Angiogenic activity of rat mammary carcinomas induced by 7, 12-dimethylbenz[ a]anthracene and its inhibition by medroxyprogesterone acetate: possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Letters 43: 85-92, 1988.
53. D'Amato RJ, Lin CM, Flynn E, et al: 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91: 3964-3968, 1994.
54. Teicher BA: A systems approach to cancer therapy. Cancer Metastasis Rev 15: 247-272, 1996.
55. Teicher BA, Dupuis N, Kusomoto T, et al: Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. radiation oncology investigations 2: 269-276, 1995.
56. Teicher BA, Emi Y, Kakeji Y, et al: TNP-470/Minocycline/cytotoxic therapy: A systems approach to cancer therapy. Eur J Cancer 32A: 2461-2466, 1996.
57. Herbst RS, Takeuchi H, Teicher BA (Subittmited 1997) Paclitaxel/ Carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemotherapy Pharmacology.